DyNoGenpharmA.com
Title
Welcome to Dynogen Pharmaceuticals, Inc.
Description
Excerpted from the website:
- Dynogen is a clinical stage pharmaceutical company developing more effective treatments for gastrointestinal (GI) and genitourinary (GU) disorders. The Company is focused on attractive and untapped markets in disease areas that severely impair a patient’s quality of life, such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD) and overactive bladder (OAB). Dynogen leverages its development expertise to identify promising clinical compounds and rapidly advance them toward registration. In February 2007, Dynogen announced that it had obtained positive Phase 2 results for DDP733 as a treatment for IBS with constipation (IBS-c).
Languages
English
Additional Information
Related Domains
External Links
Categories:
- 5
- Biopharmaceutical
- Biotech
- C-fiber
- CIC
- Chronic Idiopathic Constipation
- Clinical Trials
- DDP200
- DDP225
- DDP733
- Drug Candidates
- Drug Development
- Drug Identification
- Dynogen Pharmaceuticals Inc
- G-protein Coupled Receptors
- GERD
- GI
- GPCR
- GU
- Gastroesophageal Reflux Disease
- Gastrointestinal Diseases
- Gastrointestinal Disorders
- Genitourinary Diseases
- Genitourinary Disorders
- HT3 Agonist
- HT3 Antagonism
- HT3 Antagonist
- IBS
- Ion Channel Modulators
- Irritable Bowel Syndrome
- NARI
- Neurological Basis
- Neurology
- Neuroscience-based
- Noradrenaline Reuptake Inhibition
- OAB
- Overactive Bladder
- Predictive Pharmacology
- Prokinetic
- Pumosetrag